{"entity":{"id":"lupeng-pharmaceuticals","kind":"company","name":"Lupeng Pharmaceuticals","aka":["Guangzhou Lupeng Pharmaceutical","鲁鹏医药"],"tldr":"Lupeng Pharmaceuticals is a China-based biotechnology company that leads 4 cancer trials in OnCo, testing the Bcl-2 inhibitor lacutoclax (LP-108) and the BTK inhibitor rocbrutinib (LP-168) in chronic lymphocytic leukaemia, mantle cell lymphoma, diffuse large B-cell lymphoma and follicular lymphoma.","summary":"Lupeng Pharmaceuticals develops next-generation small-molecule targeted drugs for malignant tumours and autoimmune diseases, focused on haematological cancers and the BTK, Bcl-2 and Bcl-xL pathways. Its site states that rocbrutinib (LP-168) is approved by China's NMPA and that lacutoclax (LP-108) has entered pivotal registration studies. On ClinicalTrials.gov it is the lead sponsor of 4 trials recorded in OnCo: NCT07609823 (phase 2, A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL), NCT07609862 (phase 1/2, A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies), NCT05716087 (phase 2, A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma) and NCT07189065 (phase 2, A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.lupengbio.com/"},{"label":"ClinicalTrials.gov: trials led by Lupeng Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Guangzhou%20Lupeng%20Pharmaceutical%20Company%20LTD."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cll","mantle-cell-lymphoma","dlbcl","follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["rocbrutinib","bendamustine","rituximab","lenalidomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07609823","nct07609862","nct05716087","nct07189065"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Guangzhou","country":"CN","companyType":"biotech","website":"https://www.lupengbio.com/","stage":"growth","investors":[],"funding":[]},"route":"/companies/lupeng-pharmaceuticals/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"drug":[{"id":"bendamustine","kind":"drug","name":"Bendamustine","route":"/drugs/bendamustine/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"rocbrutinib","kind":"drug","name":"Rocbrutinib","route":"/drugs/rocbrutinib/"}],"trial":[{"id":"nct07609823","kind":"trial","name":"A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct07609823/"},{"id":"nct07609862","kind":"trial","name":"A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies","route":"/trials/nct07609862/"},{"id":"nct05716087","kind":"trial","name":"A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma","route":"/trials/nct05716087/"},{"id":"nct07189065","kind":"trial","name":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","route":"/trials/nct07189065/"}]}}